Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Orphan-drug pipelines create dense disclosures, and Travere Therapeutics鈥� filings are no exception. Pages of clinical trial data, sparsentan milestones, and liquidity notes often leave investors scanning for what matters. If you鈥檝e ever wondered where to find 鈥淭ravere Therapeutics insider trading Form 4 transactions鈥� or how the company accounts for FDA fast-track expenses in a 10-Q, this page eliminates the guesswork. The result: Travere Therapeutics SEC filings explained simply.
Stock Titan鈥檚 AI reads every document the moment it hits EDGAR, then serves plain-English explanations. From the latest 鈥淭ravere Therapeutics quarterly earnings report 10-Q filing鈥� to a sudden 鈥淭ravere Therapeutics 8-K material events explained,鈥� our algorithms highlight cash runway, trial timelines, and risk factors. AG真人官方-time alerts keep you updated on 鈥淭ravere Therapeutics Form 4 insider transactions real-time,鈥� so you don鈥檛 miss an executive stock sale filed after the bell.
Need deeper context? Our platform links each form to the business questions professionals actually ask:
- 鈥淭ravere Therapeutics annual report 10-K simplified鈥� 鈥� see R&D spend, orphan-drug market size, and revenue projections in one view.
- 鈥淭ravere Therapeutics proxy statement executive compensation鈥� 鈥� compare CEO incentives to pivotal trial milestones.
- 鈥淭ravere Therapeutics earnings report filing analysis鈥� 鈥� track quarter-over-quarter pipeline progress without reading footnotes.
- 鈥渦nderstanding Travere Therapeutics SEC documents with AI鈥� 鈥� follow guided annotations inside each filing.
- 鈥淭ravere Therapeutics executive stock transactions Form 4鈥� 鈥� monitor patterns ahead of regulatory announcements.
Whether you鈥檙e modeling probability-of-approval or simply verifying cash reserves, Stock Titan delivers complete coverage, expert context, and AI-powered summaries that turn complex disclosures into actionable insights.
Selected financial highlights (three and six months ended June 30, 2025): Total revenue was $114.4 million for Q2 and $196.2 million for the six months. Net product sales were $94.8 million in Q2 (FILSPARI $71.9M, tiopronin $23.0M) vs. $52.2M a year ago. License and collaboration revenue included a $17.5 million regulatory milestone. Operating loss for the quarter was $12.7M; six-month net loss was $53.98M (basic/diluted loss per share YTD $0.61). Cash and cash equivalents were $75.2M and available-for-sale marketable debt securities were $244.4M (total liquid investments $319.5M). Total assets were $555.3M, total liabilities $522.6M, and stockholders' equity $32.7M.
Operational and programmatic items: FILSPARI previously received full U.S. approval (Sept 5, 2024) and the European conditional MA converted to a standard MA in April 2025, triggering the $17.5M milestone in May 2025. The company submitted an sNDA seeking FSGS approval; the FDA accepted the sNDA and set a PDUFA date of Jan 13, 2026 and plans an advisory committee. Pegtibatinase enrollment is on a voluntary pause due to manufacturing scale-up issues. Renalys licensing and other collaborations remain active.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
